Citation

Oh J, O'Connor PW. Neurol. Clin. Pract. 2013; 3(3): 254-260.

Copyright

(Copyright © 2013, Lippincott Williams and Wilkins)

DOI

10.1212/CPJ.0b013e318296f299

PMID

unavailable

Abstract

Teriflunomide is a novel disease-modifying agent that was recently approved for use in the treatment of multiple sclerosis (MS). Teriflunomide has demonstrated clinical efficacy and safety in a number of large, multicenter, phase III clinical trials and is an attractive agent to add to the growing repertoire of available treatments for MS, as it has the benefit of oral administration. Furthermore, existing clinical experience with its parent drug, leflunomide, provides indirect long-term safety data. This review summarizes teriflunomide's pharmacologic properties, pivotal clinical trials, and safety profile, and ends with a discussion of the role of teriflunomide in the context of current and emerging MS treatment options. © 2013 American Academy of Neurology.

Language: en

Keywords

human; suicide; food intake; article; comparative study; clinical practice; neutropenia; priority journal; headache; drug mechanism; drug safety; placebo; drug blood level; rheumatoid arthritis; sepsis; diarrhea; nausea; drug withdrawal; theophylline; recurrence risk; side effect; duloxetine; alopecia; drug half life; oral contraceptive agent; warfarin; paclitaxel; multiple sclerosis; repaglinide; monotherapy; tizanidine; drug bioavailability; open study; alanine aminotransferase blood level; respiratory tract infection; ethinylestradiol; rheumatic disease; leflunomide; pioglitazone; fumaric acid dimethyl ester; teriflunomide; phase 2 clinical trial (topic); phase 3 clinical trial (topic)